600216.SS · 浙江医药
China A-shares · RS rating 52 · As of 2026-10-14
| Price | 12.19 CNY |
|---|---|
| 1-day change | +0.0% |
| RS rating (overall / 1M / 3M / 12M) | 52 / 56 / 63 / 49 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 20 / 12 / 15 |
| Industry group (rank) | Medical-Generic Drugs (40) |
| EPS growth Q/Q | – |
| Sales growth Q/Q | +0.2% |
| Distance from 52-week high | +33.7% |
| Market cap (USD) | $1.8B |